SUPN FY 2014 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SUPNSupernus Pharmaceuticals, Inc.

$3B

FY 2014 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$122M+915.4% YoY

Gross Profit

$116M95.3% margin

Operating Income

$24M19.9% margin

Net Income

$20M16.3% margin

EPS (Diluted)

$0.32

Cash Flow

Operating Cash Flow

$8M

Free Cash Flow

$7M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$138M

Total Liabilities

$66M

Stockholders' Equity

$71M

Cash & Equivalents

$74M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$122M	$12M	+915.4%
Gross Profit	$116M	$11M	+965.4%
Operating Income	$24M	-$62M	+139.1%
Net Income	$20M	-$92M	+121.5%